Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization.

By C. Heeschen, Alexandra Aicher, R. Lehmann, S. Fichtlscherer, M. Vasa, C. Urbich, Christiane Mildner-Rihm, H. Martin, A. Zeiher, Stefanie Dimmeler. Blood, 2003

898 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. (2005, neutral): “Heeschen et al. (30) found no differences in CD34 (cid:1) CD133 (cid:1) cells between patients with chronic myocardial ischemia and healthy controls, but reported poorer angiogenic properties of progenitor cells from patients than from controls.”
The anti-angiogenic basis of metronomic chemotherapy (2004, background): “This is because they promote the mobilization of marrow progenitor cells into the peripheral circulation, where they can differentiate into mature white blood cells such as neutrophils or red blood cells, and have been shown to increase the mobilization of CEP”
Endothelial dysfunction. (2004, background): “Of special interest for patients with chronic renal failure may be the finding that erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization (147).”